Intuitive Surgical Increases Its Direct Operations Across Europe

Intuitive Surgical Expands Direct Operations in Europe

Intuitive Surgical (ISRG) has finalized the purchase of the da Vinci and Ion distribution businesses throughout Europe, marking a significant step toward establishing its own direct operations in the region. The acquisition includes distribution activities previously managed by ab medica, Abex, Excelencia Robótica, and their affiliates in countries such as Italy, Spain, Portugal, Malta, San Marino, and related territories. With this move, Intuitive Surgical will now oversee direct operations across most of Europe, with a few exceptions.

After the acquisition, these European operations have been merged into ISRG’s regional commercial and marketing teams. Dirk Barten, the company’s Senior Vice President and General Manager, will lead the direct sales and marketing efforts in Europe.

Stock Performance Overview

Since the announcement, ISRG shares have dipped by 1.2%, reflecting broader market volatility linked to ongoing geopolitical tensions in the Middle East. Despite this, the stock has climbed 6.6% over the past six months, outperforming the medical instruments industry, which saw a 3.8% decline. Over the same timeframe, the S&P 500 Index rose by 7.4%.

Image Source: Zacks Investment Research

Company leadership believes that managing operations directly in Southern Europe will allow Intuitive Surgical to respond more swiftly to customer needs and expand access to minimally invasive procedures for more patients.

Key Developments and Growth in Europe

By the end of 2025, Intuitive Surgical had installed over 470 da Vinci surgical systems across Italy, Spain, and Portugal. The company is also expanding its Ion platform in Europe, with recent launches in Italy and Spain.

Beyond its strong U.S. presence, Intuitive Surgical has experienced consistent growth in patient treatments outside the United States over the last decade. The proportion of patients treated in international markets rose from 23% in 2015 to 35% in 2025, with Europe and Asia driving much of this increase. In 2025, 342 da Vinci systems were installed in Europe, up from 309 in 2024, while 16 Ion systems were placed, compared to 14 the previous year. These figures highlight the ongoing demand for ISRG’s robotic surgical technologies in Europe.

In July of the previous year, ISRG received European regulatory approval for its most advanced robotic system, da Vinci 5. The system has already seen strong adoption in the U.S., and similar momentum is expected in Europe, thanks to innovations such as force feedback and enhanced case insights.

The Ion system, recently introduced in Italy and Spain, has shown promising results in lung cancer care. According to ISRG, the Ion platform has significantly shortened the time from diagnosis to treatment—from over 200 days with traditional methods to just 28 days—potentially improving patient survival rates and increasing demand for the system.

With these advancements, ISRG’s direct presence in Europe positions the company to better serve healthcare providers and patients by enhancing care experiences, broadening access to minimally invasive procedures, and reducing overall treatment costs.

European Surgical Robotics Market Outlook

According to a report by Markets and Markets, the European surgical robotics market was valued at $2.10 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 14%, reaching $5.21 billion by 2031. This expansion is fueled by a growing preference for minimally invasive surgeries, an aging population, and rising rates of chronic diseases such as cancer, all of which are increasing the demand for robot-assisted procedures.

Intuitive Surgical’s established leadership in robotic surgery positions it to benefit significantly from this market growth.

Recent Updates from Intuitive Surgical

Last month, Intuitive Surgical (ISRG) secured FDA clearance for its da Vinci 5 system to be used in select cardiac procedures, including mitral valve repair and internal mammary artery mobilization for cardiac revascularization. The company plans to work with a limited number of U.S. medical centers through 2026 to launch initial da Vinci 5 cardiac programs.

Intuitive Surgical, Inc. Stock Information

ISRG’s Zacks Rank and Other Noteworthy Stocks

Intuitive Surgical currently holds a Zacks Rank #1 (Strong Buy).

Other highly ranked companies in the medical sector include:

• Globus Medical
• Pacific Biosciences of California
• Edwards Lifesciences

Globus Medical, also rated Zacks Rank #1, reported adjusted earnings per share (EPS) of $1.28 for Q4 2025, surpassing expectations by 20.8%. Revenue reached $826 million, 4.9% above estimates. The company’s projected long-term earnings growth rate is 9.6%, compared to the industry’s 14% growth. Over the last four quarters, Globus Medical exceeded earnings forecasts with an average surprise of 13.2%.

Pacific Biosciences of California, also with a Zacks Rank #1, posted a Q4 2025 adjusted loss per share of 12 cents, beating estimates by 36.8%. Revenue was $45 million, 9.4% above consensus. The company’s estimated earnings decline rate is 1.9%, while the industry is expected to improve by 11.4%. Pacific Biosciences exceeded earnings expectations in each of the last four quarters, with an average surprise of 27.7%.

Edwards Lifesciences, currently holding a Zacks Rank #2, reported adjusted EPS of 58 cents for Q2 fiscal 2026, missing estimates by 6.5%. Revenue was $1.57 billion, 2% above expectations. The company’s projected long-term earnings growth rate is 12.9%, compared to the industry’s 14%. Edwards beat earnings estimates in three of the last four quarters, with an average surprise of 5.5%.

Free Report: Capitalizing on the Next AI Boom

The upcoming phase of artificial intelligence innovation is expected to generate substantial wealth for early investors, potentially adding trillions to the global economy and transforming various industries.

Those who invested in companies like Nvidia at the right moment have already seen significant returns.

However, the rapid growth seen in the initial wave of AI stocks may soon plateau, paving the way for a new group of innovative companies to lead the next surge.

Zacks’ report, AI Boom 2.0: The Second Wave, highlights four lesser-known companies that could become major players in the next stage of AI advancement.

Additional Resources